Cargando…
Concentration‐QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers
AIMS: Given the increasing emergence of drug resistance in Plasmodium, new antimalarials are urgently required. P218 is an aminopyridine that inhibits dihydrofolate reductase being developed as a malaria chemoprotective drug. Assessing the effect of new compounds on cardiac intervals is key during e...
Autores principales: | Täubel, Jӧrg, Lorch, Ulrike, Ferber, Georg, Spencer, Christopher S., Freier, Anne, Coates, Simon, El Gaaloul, Myriam, Donini, Cristina, Chughlay, Mohamed Farouk, Chalon, Stephan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292718/ https://www.ncbi.nlm.nih.gov/pubmed/34075612 http://dx.doi.org/10.1111/bcp.14933 |
Ejemplares similares
-
First‐in‐human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection
por: Chughlay, M. Farouk, et al.
Publicado: (2020) -
Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study
por: Chughlay, Mohamed Farouk, et al.
Publicado: (2021) -
Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers
por: Täubel, Jörg, et al.
Publicado: (2021) -
Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects
por: Täubel, Jörg, et al.
Publicado: (2016) -
Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single‐Center Open‐Label, Randomized Crossover Studies in Healthy Japanese Volunteers
por: Lorch, Ulrike, et al.
Publicado: (2020)